Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of alkyldiarylamines and structurally classified as a pyridobenzodiazepine derivative. It has been studied primarily as an experimental antiviral agent targeting HIV. The mechanism of action is believed to involve inhibition of HIV reverse transcriptase by binding to the non-nucleoside inhibitor binding pocket (NNIBP), thereby blocking viral replication. It is not approved for clinical use and remains an experimental compound[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6,11-dihydro-11-ethyl-6-methyl-9-nitro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one.